Ma graduatoria dopo il primo semestre sulla base dell’esito degli esami
Risultati per: Nuovo test del sangue per la diagnosi di cancro alla prostata
Questo è quello che abbiamo trovato per te
La difficile diagnosi di Adhd nell'adulto, il 25% tema di averla
Non solo un problema dei bimbi ma “attenzione all’autodiagnosi”
Predicting mucosal inflammation in IBD patients using patient-reported symptom scores and a faecal calprotectin home test: protocol for a multicentre prospective validation study
Introduction
Crohn’s disease and ulcerative colitis are chronic inflammatory bowel diseases (IBD) with a relapsing-remitting nature. With adequate non-invasive prediction of mucosal inflammation, endoscopies can be prevented and treatment optimised earlier for better disease control. We aim to validate and recalibrate commonly used patient-reported symptom scores combined with a faecal calprotectin (FC) home test as non-invasive diagnostic tool for remote monitoring of IBD, both in daily practice and in a strict trial setting. Endoscopy will be used as the gold standard.
Methods and analysis
In this multicentre prospective validation study, adult IBD patients are asked to fill out questionnaires regarding disease activity (Monitor IBD At Home, mobile Health Index, Manitoba IBD Index, IBD control and patient-HBI/patient-Simple Clinical Colitis Activity Index), perform a FC home test and collect a stool sample for routine laboratory FC measurement, before the start of the bowel preparation for the ileocolonoscopy. Endoscopic disease activity will be scored according to the simplified endoscopic score for Crohn’s disease (CD) for CD patients or Ulcerative Colitis Endoscopic Index for Severity and Mayo Endoscopic Subscore for ulcerative colitis patients. The main study outcome is the diagnostic test accuracy of the various patient-reported scores to assess mucosal inflammation in combination with a FC home test.
Ethics and dissemination
This study is approved by the Medical Research Ethics Committee of azM/UM in Maastricht dated 03 March 2021 (METC 20–085) and is monitored by the Clinical Trial Centre Maastricht according to Good Clinical Practice guidelines. Written informed consent will be obtained from all patients. Study results will be published in international peer-reviewed medical journals.
Trial registration number
NCT05886322
FDA Greenlights First At-Home Syphilis Test to Help Speed Up Diagnoses
The US Food and Drug Administration (FDA) approved the first at-home test for syphilis for sale without a prescription. The test, manufactured by NOWDiagnostic and called First To Know Syphilis Test, arrives amid an 80% increase in cases in the US between 2018 and 2022, from 115 000 to 207 000 cases.
Antibiotici, nel 90% dei casi allergia mai accertata con un test
Allergologi, ‘falsi allergici’ costretti a farmaci meno efficaci
Percorsi personalizzati contro il cancro legati al gene BRCA
Cancro al seno, l'IA svela chi lo svilupperà dalle mammografie
Accuratezza pari o maggiore dei calcolatori in uso
Shortfalls in Follow-up Albuminuria Quantification After an Abnormal Result on a Urine Protein Dipstick Test
Annals of Internal Medicine, Ahead of Print.
Shortfalls in Follow-up Albuminuria Quantification After an Abnormal Result on a Urine Protein Dipstick Test
Annals of Internal Medicine, Ahead of Print.
Tumori al seno, diagnosi in ritardo per il 20% delle immigrate. Il 39% non esegue la mammografia
Per l’86% degli oncologi sono troppe le disparità di accesso alle cure
Tumori al seno, diagnosi in ritardo per il 20% delle immigrate
Per 86% oncologi sono troppe le disparità di accesso alle cure
La regina di Spagna a Milano per la ricerca contro il cancro
Visita all’Istituto di oncologia molecolare di Fondazione Airc
The Impact of Population-Based Helicobacter pylori Test-To-Treat Strategies on Gastric Cancer Outcomes
L'infertilità non è una colpa, i consigli per affrontare la diagnosi
Il 22 settembre si celebra la Giornata nazionale di informazione
Diagnosi di Alzheimer: dai biomarcatori di resilienza all’analisi del linguaggio
La ricerca sulla comprensione e sulla gestione di questa malattia neurodegenerativa si apre ai fattori di protezione e allo screening con l’intelligenza artificiale
Alzheimer, solo 2 pazienti su 10 ricevono diagnosi precoce
“Imparare a intercettare i primi segnali, spesso sottovalutati”